[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cytomegalovirus-cmv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cytomegalovirus-cmv":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,43,65,89,120,144,164,187,212,233,253],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100577040","comparison-diagnostic-tests-for-the-diagnosis-of-cytomegalovirus-organ-disease-in-patients-with-intestinalbowel-diseases-100577040",false,"NCT06793124","Comparison Diagnostic Tests for the Diagnosis of CYTOmegalovirus Organ Disease in Patients With intestinalBOweL Diseases","Comparison of Diagnostic Tests for the Diagnosis of CYTOmegalovirus Organ Disease in Patients With Intestinal BOweL Diseases","CYTO-BOLD","Inclusion Criteria:\n\n* Patients aged ≥18 years with Inflammatory Bowel Disease (IBD) with worsening of IBD-related symptoms requiring hospital admission\n* Signing of informed consent\n* Performed endoscopic biopsies to confirm\u002Fexclude CMV organ disease\n\nExclusion Criteria: \u002F","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","Observational, single-center, non-pharmacological, prospective study of adult patients affected by Inflammatory Bowel Disease (IBD) with an ongoing disease exacerbation requiring hospitalization",[25,26],"Cytomegalovirus (CMV)","Inflammatory Bowel Disease (IBD)",[25,26,28,29],"PCR","Tissue biopsy","RECRUITING","2026-06-11",{"date":33,"type":34},"2026-06-15","ACTUAL",{"date":36,"type":34},"2024-04-02",{"date":38,"type":21},"2026-12-31",{"name":40,"class":41},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":42},"100532528","a-study-of-maribavir-in-adults-and-children-with-post-transplant-cytomegalovirus-cmv-infection-in-argentina-100532528","NCT06213974","A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina","Post Authorization Study to Monitor Efficacy, Effectiveness, and Safety of Maribavir (LIVTENCITY®) in Patients With Post-transplant Cytomegalovirus (CMV) Infection in Argentina","Inclusion Criteria:\n\n* Adult participants (18 years or older) and pediatric participants (12 years of age and older and weighing at least 35 kilogram \\[kg\\]) with post-transplant CMV infection\u002Fdisease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in the real-world setting of common clinical practice in Argentina.\n* Have received at least one dose of maribavir according to approved indications.\n* Have signed the mandatory informed consent\u002Fassent that has been agreed with national regulatory authorities (ANMAT) as applicable.\n\nExclusion Criteria\n\n\\- There are no specific exclusion criteria.","12 Years",{"count":52,"type":21},10,"The main aim of this study is to learn about the safety of Maribavir in adults and children with post-transplant CMV infection in routine clinical practice in Argentina.\n\nThe other aim is to study the effectiveness of the treatment with Maribavir in routine clinical practice in Argentina.\n\nParticipants will be treated by their doctors according to normal medical practice. Study data will be collected either from information already available in the medical records or during study conduct.",[25],"2026-06-02",{"date":57,"type":34},"2026-06-04",{"date":59,"type":34},"2024-09-03",{"date":61,"type":21},"2026-07-31",{"name":63,"class":64},"Takeda","INDUSTRY",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100463796","phase-3-a-study-to-evaluate-the-safety-and-tolerability-pharmacokinetics-and-antiviral-activity-of-maribavir-for-the-treatment-of-cytomegalovirus-cmv-infection-in-children-and-adolescents-who-have-received-a-hematopoietic-stem-cell-transplant-hsct-or-a-solid-organ-transplant-sot-100463796","NCT05319353","A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)","A Phase 3, Open-label, Single-arm, Repeated-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)","Inclusion Criteria:\n\n* Parent\u002Fboth parents or legally authorized representative (LAR) must provide signature of informed consent and there must be documentation of assent by the participant, as age appropriate, before completing any study-related procedures.\n* Be a male or female child or adolescent \\\u003C 18 years of age at the time of consent. For participants in Cohort 3 only (0 to \\\u003C6 years) must have a gestational age of at least 39 weeks and a minimum weight of 5 kg.\n* Be a recipient of an SOT or an HSCT that is functioning at the time of screening.\n* Have a documented CMV infection which may be a first episode of post-transplant CMV viremia (primary or reactivation) or refractory to other anti-CMV treatments, with a CMV DNA screening value of \\>= 1365 International Units per milliliter (IU\u002FmL) in whole blood or \\>= 455 IU\u002FmL in plasma in 2 consecutive assessments separated by at least 1 day, as determined by local laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative nucleic acid amplification test (qNAAT) results. Quantitative assays must be standardized to the World Health Organization (WHO) CMV International Standard. Both samples must be taken within 14 days of first dose of study drug, with the second sample obtained within 5 days prior to first dose of study drug. The same laboratory and same sample type (whole blood or plasma) must be used for both assessments. If documented and verified values are available in medical history that fulfill this criterion entirely, they may be used instead.\n* Have all the following results as part of screening laboratory assessments:\n* Absolute neutrophil count \\>= 500 per cubic millimeter (\u002Fmm\\^3) (0.5 × 10\\^9 per liter \\[\u002FL\\])\n* Platelet count \\>= 15,000\u002Fmm\\^3 (15 × 10\\^9\u002FL)\n* Hemoglobin \\>= 8 grams per deciliter (g\u002FdL) (\\>=80 grams per liter \\[g\u002FL\\]).\n* Have an estimated glomerular filtration rate (creatinine-based Bedside Schwartz equation) \\>= 30 milliliters per minute (mL\u002Fmin) \u002F1.73 meter square (m\\^2).\n* Be a female of nonchildbearing potential. If a female of childbearing potential, have a negative serum human chorionic gonadotropin (hCG) or beta-human chorionic gonadotropin (β-hCG) pregnancy test at screening. Males, or nonpregnant, nonlactating females who are sexually active must agree to comply with the applicable contraceptive requirements of this protocol during the study treatment administration period and for 90 days after the last dose of study treatment.\n* Have life expectancy of \\>= 8 weeks.\n* Be willing and have an understanding and ability to fully comply with the study procedures and restrictions defined in the protocol. For younger children, the parent\u002Fboth parents or LAR must meet this criterion.\n* Participants must have a confirmed negative human immunodeficiency virus (HIV) test result within 3 months of first dose of study drug or, if unavailable, be tested by a local laboratory during the screening period.\n\nExclusion Criteria:\n\n* Have CMV tissue invasive disease involving the central nervous system (CNS) or retina as assessed by the investigator at the time of screening.\n* Have uncontrolled other type of infection as assessed by the investigator on the date of enrollment.\n* Have a history of clinically relevant alcohol or drug abuse that may interfere with treatment compliance or assessments with the protocol as determined by the investigator.\n* Be receiving valganciclovir, ganciclovir, cidofovir, foscarnet, leflunomide, letermovir, or artesunate when study treatment is initiated, or anticipated to require one of these agents during the 8-week treatment period.\n* Have a known hypersensitivity to maribavir or to any excipients.\n* Have severe vomiting, diarrhea, or other severe gastrointestinal (GI) illness within 24 hours prior to the first dose of study treatment or a GI absorption abnormality that would preclude administration of oral medication.\n* Require mechanical ventilation or vasopressors for hemodynamic support at baseline (Visit 2\u002FDay 1\u002FWeek 0).\n* Be pregnant (or expecting to conceive) or nursing.\n* Have previously completed, discontinued, or have been withdrawn from this study.\n* Have received any investigational agent or device within 30 days before initiation of study treatment (includes CMV specific T-cells) or plan to receive an investigational agent or device during the study.\n\nPreviously approved agents under investigation for additional indications are not exclusionary.\n\n* Have previously received maribavir or CMV vaccine at any time.\n* Have any clinically significant medical or surgical condition that, in the investigator's opinion, could interfere with interpretation of study results, contraindicate the administration of the study treatment, or compromise the safety or well-being of the participant.\n* Have severe liver disease (Child-Pugh score of \\>= 10).\n* Have serum aspartate aminotransferase greater than (\\>) 5 times upper limit of normal (ULN) at screening, or serum alanine aminotransferase \\> 5 times ULN at screening, or total bilirubin \\>= 3.0 times ULN at screening (except for documented Gilbert's syndrome), as analyzed by local laboratory.\n* Have positive results for HIV.\n* Have active malignancy with the exception of nonmelanoma skin cancer, as determined by the investigator. Participants who experience relapse or progression of their underlying malignancy (for which HSCT or SOT was performed), as determined by the investigator, are not to be enrolled.\n* Be undergoing treatment for acute or chronic hepatitis B or hepatitis C.\n* Requiring ongoing treatment with or an anticipated need for treatment with a strong cytochrome P450 3A (CYP3A) inducer.\n* Have a low body weight where total blood volume (TBV) required during study participation will exceed 1 percent (%) TBV per study visit or 3% TBV over a 4-week period.","17 Years",{"count":74,"type":21},80,"INTERVENTIONAL",[77],"PHASE3","The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in children and teenagers after HSCT or SOT and to identify the optimal dose of maribavir using a 200 milligrams (mg) tablet formulation or powder for oral suspension.\n\nThe participants will be treated with maribavir for 8 weeks.\n\nParticipants need to visit their doctor during 12-week follow-up period.",[25],"2026-05-20",{"date":82,"type":34},"2026-05-22",{"date":84,"type":34},"2023-11-13",{"date":86,"type":21},"2027-01-18",{"name":63,"class":64},53,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":75,"phases":99,"briefSummary":101,"conditions":102,"keywords":106,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100632433","phase-2-systemic-and-topical-antiviral-control-of-cytomegalovirus-anterior-uveitis-treatment-outcomes---trials-i-and-ii-100632433","NCT07513623","Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II","STACCATO I\u002FII","Inclusion Criteria:\n\nTrial I - Inclusion Criteria\n\n* Age at or above the age of majority at the time of enrollment (≥18 years of age in the United States; ≥20 years of age in Thailand and Taiwan)\n* Presenting with active anterior uveitis, defined as ≥1+ anterior chamber cell per -Standardization of Uveitis Nomenclature (SUN) Working Group criteria, in one or both eyes at the time of screening\n* Clinical features suggestive of a viral etiology for anterior uveitis, as determined by the treating study ophthalmologist, including but not limited to one or more of the following:\n* Unilateral hypertensive uveitis (elevated intraocular pressure in the setting of anterior chamber inflammation)\n* Coin-shaped or stellate keratic precipitates\n* Iris atrophy\n* Corneal endothelial changes consistent with CMV endotheliitis\n* Detection of cytomegalovirus (CMV) DNA by directed polymerase chain reaction (PCR) testing of aqueous humor obtained via anterior chamber paracentesis at the screening visit (Exam 0), as determined by local site PCR testing\n* Willingness and ability to provide written informed consent prior to enrollment and prior to any research-specific procedures\n* Willingness and ability to comply with study visit schedule, medication regimen, and study procedures for the duration of Trial I (21 days)\n* For participants of reproductive potential:\n* Female participants must agree to use at least one effective method of contraception during the study treatment period and for at least 30 days following the last dose of study medication\n* Male participants with female partners of reproductive potential must agree to use barrier contraception during the study treatment period and for at least 90 days following the last dose of study medication\n\nTrial II - Inclusion Criteria\n\nParticipants may enter Trial II via one of two pathways. All participants must meet the following general inclusion criteria:\n\n* Age at or above the age of majority (≥18 years of age in the United States; ≥20 years of age in Thailand and Taiwan)\n* Prior confirmed diagnosis of CMV anterior uveitis, established by positive PCR testing for CMV DNA in aqueous humor obtained via anterior chamber paracentesis during an active episode of anterior uveitis (uveitis flare). This confirmation may have been established either:\n* During participation in Trial I of the current study, or\n* Prior to enrollment directly into Trial II, in which case documentation of a prior positive aqueous CMV PCR result is required\n* Currently clinically inactive anterior uveitis, defined as ≤0.5+ anterior chamber cell per SUN criteria, sustained for a minimum of 2 weeks prior to enrollment into Trial II\n* Completion of a minimum 2-week washout period free from all antiviral therapy prior to randomization into Trial II\n* Willingness and ability to provide written informed consent for Trial II participation (a separate consent process from Trial I) prior to enrollment and prior to any Trial II-specific research procedures\n* Willingness and ability to comply with the Trial II visit schedule, medication regimen, and study procedures for the duration of the 12-month follow-up period\n* For participants of reproductive potential:\n* Female participants must agree to use at least one effective method of contraception during the study treatment period and for at least 30 days following the last dose of study medication\n* Male participants with female partners of reproductive potential must agree to use barrier contraception during the study treatment period and for at least 90 days following the last dose of study medication\n\nExclusion Criteria:\n\nTrial I - Exclusion Criteria\n\n* Inactive anterior uveitis (≤0.5+ anterior chamber cell per SUN criteria) at the time of screening or enrollment\n* Intermediate uveitis, posterior uveitis, or panuveitis as the primary diagnosis, with or without concurrent anterior segment involvement\n* Detection of herpes simplex virus (HSV) or varicella zoster virus (VZV) by directed PCR testing of aqueous humor obtained at the screening paracentesis, regardless of whether CMV is also detected\n* Receipt of any antiviral therapy (systemic or topical ophthalmic) within 14 days prior to the screening visit\n* Receipt of a periocular or intraocular corticosteroid injection within 8 weeks prior to the screening visit\n* Current use of systemic immunosuppressive therapy, including but not limited to systemic corticosteroids (at doses exceeding the equivalent of prednisone 10 mg\u002Fday), immunomodulatory agents (e.g., methotrexate, mycophenolate mofetil, azathioprine, cyclosporine), or biologic agents\n* Known immunocompromising condition, including but not limited to:\n* Human immunodeficiency virus (HIV) infection, regardless of CD4 count or viral load\n* Solid organ or hematopoietic stem cell transplant recipient\n* Active malignancy requiring chemotherapy or radiation therapy\n* Primary or acquired immunodeficiency disorder\n* Abnormal screening laboratory values, specifically:\n* Absolute neutrophil count (ANC) \\\u003C 500 cells\u002FµL\n* Platelet count \\\u003C 25,000\u002FµL\n* Hemoglobin \\\u003C 8 g\u002FdL\n* Serum creatinine \\> 2.5 mg\u002FdL or estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m²\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 5 times the upper limit of normal\n* Pregnancy or breastfeeding at the time of screening or enrollment. A negative pregnancy test is required for all female participants of reproductive potential prior to enrollment.\n* Known hypersensitivity or prior serious adverse reaction to ganciclovir, valganciclovir, acyclovir, or any component of the study medications\n* Recent or planned ocular surgery in the study eye within 30 days prior to enrollment or anticipated within the 21-day Trial I study period\n* Known autoimmune disease that could independently cause anterior uveitis (e.g., HLA-B27-associated uveitis, sarcoidosis, Behçet's disease, juvenile idiopathic arthritis-associated uveitis), unless CMV is confirmed as the causative agent by positive aqueous PCR and the treating ophthalmologist determines that CMV anterior uveitis is the primary diagnosis\n* Inability or unwillingness to comply with study visit schedule, medication regimen, or study procedures\n* Participation in another interventional clinical trial involving an investigational drug or device within 30 days prior to enrollment, or concurrent participation in another interventional clinical trial\n* Any medical, psychological, or social condition that, in the opinion of the principal investigator or site investigator, would compromise the participant's ability to safely participate in the study, adhere to the study protocol, or provide valid informed consent\n\nTrial II - Exclusion Criteria\n\n* Active anterior uveitis at the time of enrollment into Trial II, defined as ≥1+ anterior chamber cell per SUN criteria\n* Failure to achieve a minimum of 2 weeks of clinical inactivity (≤0.5+ anterior chamber cell) prior to enrollment into Trial II\n* Failure to complete a minimum 2-week washout period free from all antiviral therapy prior to randomization into Trial II\n* No documented prior PCR-confirmed diagnosis of CMV anterior uveitis in aqueous humor obtained during an active episode of inflammation (uveitis flare), either during Trial I participation or prior to direct Trial II enrollment\n* Receipt of any antiviral therapy within 14 days prior to the Trial II enrollment visit (i.e., the 2-week washout requirement has not been met)\n* Current use of systemic immunosuppressive therapy, including systemic corticosteroids at doses exceeding the equivalent of prednisone 10 mg\u002Fday, immunomodulatory agents, or biologic agents, at the time of Trial II enrollment\n* Known immunocompromising condition as defined in Trial I exclusion criterion 7 above\n* Abnormal laboratory values at the time of Trial II enrollment screening, using the same thresholds as defined in Trial I exclusion criterion 8 above\n* Pregnancy or breastfeeding at the time of Trial II enrollment. A negative pregnancy test is required for all female participants of reproductive potential prior to Trial II randomization.\n* Known hypersensitivity or prior serious adverse reaction to ganciclovir, valganciclovir, acyclovir, or any component of the study medications\n* Recent or planned ocular surgery in the study eye within 30 days prior to Trial II enrollment or anticipated within the first 3 months of the Trial II follow-up period Inability or unwillingness to comply with the Trial II visit schedule, medication regimen, or study procedures for the 12-month follow-up period\n* Participation in another interventional clinical trial involving an investigational drug or device concurrent with Trial II participation, or within 30 days prior to Trial II enrollment\n* Any medical, psychological, or social condition that, in the opinion of the principal investigator or site investigator, would compromise the participant's ability to safely participate in Trial II, adhere to the study protocol, or provide valid informed consent",true,{"count":98,"type":21},117,[100],"PHASE2","The goal of this clinical trial is to compare antiviral treatment strategies for cytomegalovirus (CMV) anterior uveitis - a viral infection causing inflammation inside the front of the eye - in immunocompetent adults aged 18 years and older. The main questions it aims to answer are:\n\nDoes oral valganciclovir reduce aqueous humor CMV viral load more effectively than topical ganciclovir 2% eye drops or placebo after 7 days of treatment (Trial I)? Does long-term suppressive antiviral therapy (oral valganciclovir or topical ganciclovir 2% eye drops) reduce the rate of CMV anterior uveitis recurrence over 12 months compared to placebo (Trial II)?\n\nResearchers will compare oral valganciclovir, topical ganciclovir 2% eye drops, and placebo to see if either antiviral treatment reduces viral load and controls eye inflammation more effectively in the short term, and whether long-term antiviral suppression can prevent the disease from coming back after the inflammation has been controlled.\n\nParticipants will:\n\n* Undergo anterior chamber paracentesis (removal of a small amount of fluid from the front of the eye) for PCR testing to confirm CMV as the cause of their eye inflammation before enrollment\n* Be randomly assigned to receive oral valganciclovir 900 mg twice daily, topical ganciclovir 2% eye drops six times daily, or placebo for 7 days (Trial I), in addition to standard steroid eye drops\n* Return for follow-up visits at Day 7 and Day 21 for eye examinations, laboratory blood tests, and a second anterior chamber paracentesis at Day 7 to measure viral load after treatment\n* If eye inflammation is controlled after Trial I, be offered enrollment into Trial II, where they will be randomly assigned to long-term suppressive oral valganciclovir, topical ganciclovir 2% eye drops, or placebo for 12 months, with follow-up visits approximately every 2 months and additional visits if inflammation returns",[25,103,104,105],"Anterior Uveitis","Infectious Uveitis","CMV Infection",[107,108],"Infectious uveitis","CMV anterior uveitis","NOT_YET_RECRUITING","2026-03-30",{"date":112,"type":34},"2026-04-07",{"date":114,"type":21},"2026-07-01",{"date":116,"type":21},"2032-10-31",{"name":118,"class":41},"University of California, San Francisco",6,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":75,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100577485","phase-3-kidney-transplant-preemptive-therapy-or-prophylaxis-for-cmv-prevention-in-dr-recipients-100577485","NCT06798909","Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients","Kidney Transplant Preemptive Therapy or Prophylaxis (KPoP) for CMV Prevention in D+R- Recipients","KPoP","Inclusion Criteria:\n\n1. Subject or legally authorized representative has provided written informed consent.\n2. Age ≥ 18 years of age at the time of informed consent.\n3. Negative for IgG antibody to CMV as assessed in a CLIA-certified laboratory between 28 days prior to transplant and up to 7 days post-transplant but prior to randomization.\n4. Received a kidney transplant from a CMV seropositive (IgG positive) donor in the past 7 days prior to enrollment\n5. Individuals of reproductive (childbearing) potential must have a negative pregnancy test (serum or urine) collected prior to randomization (SOC results within 7 days prior to transplant may be used), and must also agree to use a medically approved method of contraception. Acceptable methods include: barrier method, intrauterine device (hormonal or non-hormonal), oral hormonal contraceptives, abstinence from the time of enrollment through until discontinuation of ganciclovir or valganciclovir in either arm during the intervention period.\n\n   NOTE: Individuals of reproductive potential are defined as individuals who have reached menarche and who have not been post-menopausal for at least 12 consecutive months with follicle stimulating hormone (FSH) ≥40 IU\u002FmL or 24 consecutive months if an FSH is not available, i.e., who have had menses within the preceding 24 months, and have not undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, or salpingectomy).\n6. If male, must agree to practice a barrier method of contraception or abstinence from the time of enrollment through 3 months after discontinuation of ganciclovir or valganciclovir in either arm during the intervention period.\n\nExclusion Criteria:\n\n1. In the opinion of the investigator, participants who are unable or unwilling to undergo preemptive therapy protocol (weekly CMV PCR, etc.)\n2. Patients who are breastfeeding or planning to breastfeed within 6 months post-transplant\n3. Allergy to valganciclovir\u002Fganciclovir or Letermovir\n4. Receipt of immunoglobulin or CMV-specific immunoglobulin within the last 3 months (this includes COVID convalescent plasma)\n5. Currently enrolled or anticipated enrollment in another interventional study that, in the opinion of scientific leadership team, could affect evaluation of the primary safety and\u002For efficacy outcomes.\n6. Most recent platelet count post-transplant \\\u003C25,000\u002FuL\n7. Most recent ANC performed post-transplant \\\u003C1000\u002FuL\n8. Multi-organ transplant (except simultaneous kidney-pancreas) within the past 7 days\n9. Prior or planned receipt of a hematopoietic cell transplant\n10. Baseline immunodeficiency prior to transplant, including but not limited to:\n\n    1. Known or suspected HIV infection\n    2. Congenital or acquired immunodeficiency\n11. Unacceptable immunosuppression\n\n    1. Receipt of desensitization therapy prior to kidney transplant, or\n    2. Receipt of an ABO-incompatible kidney transplant except A2 to blood type B",{"count":129,"type":21},360,[77],"This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR). Patients meeting study eligibility criteria and who have provided informed consent will be randomized (1:1) within 7 days of transplant to receive, in an open label design, either AP with valganciclovir 900 mg orally once daily or letermovir 480 mg orally once daily \\[both dose adjusted per Food and Drug Administration (FDA) label\\] for 200 days post-transplant), or PET (central lab weekly plasma polymerase chain reaction (PCR) monitoring for CMV deoxyribonucleic acidemia (DNAemia)) for 100 days post-transplant, with oral valganciclovir 900mg orally twice daily (or renally dosed per FDA label) at onset of CMV DNAemia at any level and continued until plasma CMV DNAemia is negative or below the level of quantitation in two consecutive weekly plasma samples. Study participants will be followed for pre-specified outcomes (clinical, laboratory, immunologic, safety) until withdrawal, death, or study closure, up to a maximum of 5.5 years post-transplant. Approximately 360 participants (180 participants in each group) will be randomized into the study.\n\nEstimated Time to Complete Enrollment: 4 years",[25,133,134],"Kidney Transplant; Complications","Kidney Diseases","2026-03-26",{"date":137,"type":34},"2026-04-01",{"date":139,"type":34},"2025-07-22",{"date":141,"type":21},"2031-05-31",{"name":118,"class":41},5,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":75,"phases":153,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":162,"locationsCount":163},"100549844","phase-3-a-study-of-maribavir-in-chinese-adults-with-cytomegalovirus-cmv-infections-100549844","NCT06439342","A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections","An Open-label, Single-arm Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Maribavir in Chinese Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Cidofovir or Foscarnet","Inclusion Criteria\n\n* The participant or the participant's legally acceptable representative is willing and able to understand and fully comply with study procedures and requirements, in the opinion of the investigator.\n* The participant\u002Fparticipant's legally representative has provided informed consent (that is, in writing, documented via a signed and dated informed consent form \\[ICF\\]) and any required privacy authorization prior to the initiation of any study procedures.\n* The participant is aged 18 years or older (ie, greater than or equal to \\[\\>=\\] 18 years) at the time of signing the ICF.\n* The participant must be of Chinese descent, defined as born in China and having Chinese parents and Chinese maternal and paternal grandparents.\n* The participant must be a recipient of hematopoietic stem cell or solid organ transplant.\n* The participant must have a documented CMV infection in whole blood or plasma, with a screening value of \\>=1,365 International unit per milliliter IU\u002FmL in whole blood or \\>=455 IU\u002FmL in plasma in 2 consecutive assessments, separated by at least 1 day, as determined by local laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative CMV DNA results. Both samples should be taken within 14 days prior to receiving the investigational product with second sample obtained within 5 days prior to receiving the investigational product. The same laboratory and same sample type (whole blood or plasma) must be used for these assessments.\n* The participant must have a current CMV infection that is refractory to the most recently administered of the 4 anti-CMV treatment agent(s) eg, intravenous (IV) ganciclovir\u002Foral valganciclovir, IV foscarnet, or IV cidofovir. Refractory is defined as documented failure to achieve greater than (\\>) 1 log10 (common logarithm to base 10) decrease in CMV DNA level in whole blood or plasma after a 14 day or longer treatment period with the above 4 agents.\n* Participants who have documentation of 1 or more CMV genetic mutations associated with resistance to ganciclovir\u002Fvalganciclovir, cidofovir, or foscarnet must also meet the definition of refractory CMV infection.\n* Have all the following results as part of screening laboratory assessments:\n\n  * Absolute neutrophil count \\>=1000 per cubic millimeter (\u002Fmm\\^3) (1\\*10\\^9 per liter \\[\u002FL\\]).\n  * Platelet count \\>= 25,000\u002Fmm\\^3 (25\\*10\\^9\u002FL)\n  * Hemoglobin \\>= 8 grams per deciliter (g\u002FdL)\n  * Estimated glomerular filtration rate \\>= 30 milliliter per minute per 1.73 square meter (mL\u002Fmin\u002F1.73 m\\^2) as assessed by Modification of Diet in Renal Disease (MDRD) formula.\n* The participant must have life expectancy of at least 8 weeks.\n* The participant has a body weight of at least 35 kilogram (kg).\n* The female participant either be of nonchildbearing potential, or if of childbearing potential then have a negative serum human chorionic gonadotropin (hCG) or beta-hCG (β-hCG) pregnancy test at screening. Males, or nonpregnant, nonlactating female participants who are sexually active must agree to comply with the applicable contraceptive requirements of this protocol during the investigational product administration period and for 90 days after the last dose of investigational product.\n* The participant must be able to swallow tablets, or receive tablets crushed and\u002For dispersed in water via a nasogastric or orogastric tube.\n\nExclusion Criteria:\n\n* The participant has CMV disease with central nervous system (CNS involvement) (eg, CMV encephalitis) or ophthalmic involvement (eg, CMV retinitis) as assessed by the investigator at the time of screening.\n* That participant has uncontrolled other type of infection as assessed by the investigator on the date of treatment assignment.\n* The participant has a history of clinically relevant alcohol or drug abuse that may interfere with treatment compliance or assessments with the protocol as determined by the investigator.\n* The participant has a known hypersensitivity to maribavir or to any excipients.\n* The participant has severe vomiting, diarrhea, or other severe gastrointestinal (GI) illness within 24 hours prior to the first dose of investigational product or a GI absorption abnormality that would preclude administration of oral medication.\n* The participant has any clinically significant medical or surgical condition that, in the investigator's opinion, could interfere with interpretation of study results, contraindicate the administration of the investigational product, or compromise the safety or well-being of the participant.\n* The participant is receiving valganciclovir, ganciclovir, cidofovir, foscarnet, letermovir, leflunomide, or artesunate when investigational product is initiated, or anticipated to require one of these agents during the 8-week treatment period.\n* The participant requires mechanical ventilation or vasopressors for hemodynamic support at the time of baseline.\n* The participant has previously received maribavir.\n* The participant has previously completed, discontinued, or have been withdrawn from this study.\n* The participant has received any investigational agent with known anti-CMV activity within 30 days before initiation of investigational product or CMV vaccine at any time.\n* The participant has received any investigational agent or device within 30 days before initiation of investigational product.\n* The participant has serum aspartate aminotransferase (AST) \\>5 times upper limit of normal (ULN) at screening, or serum alanine aminotransferase (ALT) \\>5 times ULN at screening, or total bilirubin \\>=3.0 × ULN at screening (except for documented Gilbert's syndrome), by a local laboratory. Note: Participants with biopsy confirmed CMV hepatitis will not be excluded from study participation despite AST or ALT \\>5 times ULN at screening.\n* The participant has known (previously documented) positive results for human immunodeficiency virus (HIV). Participant must have a confirmed negative HIV test result within 3 months of study entry or, if unavailable, be tested by a local laboratory during the screening period.\n* The participant has active malignancy with the exception of nonmelanoma skin cancer, as determined by the investigator. Participants who experience relapse or progression of their underlying malignancy (for which hematopoietic stem-cell transplantation (HSCT) or solid organ transplant (SOT) was performed), as determined by the investigator, are not to be enrolled.\n* The participant is undergoing treatment for acute or chronic hepatitis C and hepatitis B.\n* The participant is pregnant or expecting to conceive or nursing\u002Fbreastfeeding.",{"count":152,"type":21},20,[77],"The main aim of this study is to learn how safe maribavir is in Chinese adults who have undergone hematopoietic stem cell or organ transplantation and have a cytomegalovirus (CMV) infection and how well they tolerate treatment with maribavir. Other aims are to see how effective maribavir is in treating CMV infection and getting rid of the symptoms, the recurrence rate of CMV infection after treatment with maribavir and if the treatment is required again. Researchers will also check for changes (mutations) occurring in the virus which may cause treatment with maribavir to no longer work well or to not work at all (resistance to maribavir).\n\nThe participants will be treated with maribavir for 8 weeks.\n\nDuring the study, participants will visit their study clinic 18 times.",[25],"2026-02-26",{"date":158,"type":34},"2026-03-02",{"date":160,"type":34},"2024-12-16",{"date":38,"type":21},{"name":63,"class":64},12,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},"100534815","a-study-of-maribavir-in-adults-with-kidney-failure-who-have-a-cytomegalovirus-cmv-infection-after-transplantation-100534815","NCT06243731","A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation","Retrospective Chart Review of Safety Outcomes Associated With Use of Maribavir in Patients With Post-transplant Refractory Cytomegalovirus (CMV) Infection and Comorbid Severe Chronic Kidney Disease (CKD) or Comorbid End-stage Renal Disease (ESRD), Including Patients on Peritoneal Dialysis or Hemodialysis","Inclusion Criteria:\n\n* Adults more than and equal to (≥) 18 years of age at index date.\n* Diagnosis of comorbid ESRD or comorbid severe CKD prior to the index date.\n\n  * If ESRD (including participants on peritoneal dialysis or hemodialysis): participant diagnosed with ESRD confirmed by an estimated glomerular filtration rate (eGFR) less than (\\\u003C) 15 milliliters per minute per 1.73 square meters (mL\u002Fmin\u002F1.73m\\^2).\n  * If severe CKD: participant diagnosed with severe CKD confirmed by an eGFR of 15 to \\\u003C30 mL\u002Fmin\u002F1.73m\\^2 at index.\n* Participant has undergone solid organ transplant (SOT) or hematopoietic stem cell transplantation (HSCT) before index date.\n* Participant was diagnosed with refractory (with or without resistance) CMV during the latest post-transplant period.\n* Participant initiated treatment with maribavir in routine practice within the eligibility period and received at least 1 dose of maribavir.\n* Informed consent provided (where required by local regulations) before data collection commences.\n\nExclusion Criteria:\n\nThere are no exclusion criteria for this study.",{"count":52,"type":21},"The main aim of this study is to assess the safety of maribavir in adults with severe CKD or comorbid ESRD including participants on artificial filtering of the kidney (dialysis) or the blood (hemodialysis).\n\nIn this study, already existing data will be collected from the participant's medical records. The study will only review data collected as part of the normal clinical routine and will not impact the standard medical care and treatment of participants.",[25,174,175],"Kidney Disease","Kidney Failure",[177],"Drug therapy","2025-12-08",{"date":180,"type":34},"2025-12-16",{"date":182,"type":34},"2025-11-03",{"date":184,"type":21},"2027-01-31",{"name":63,"class":64},25,{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":195,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":75,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":42},"100594044","phase-2-phase-ii-trial-of-maribavir-for-cmv-in-patients-with-lymphoid-malignancy-on-bispecific-antibodies-100594044","NCT07014319","Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies","Maribavir Treatment of Cytomegalovirus for Lymphoid Malignancy Patients Undergoing Bispecific Antibodies","MALMBA","Inclusion Criteria:\n\n* Subject is ≥19 years of age at the time of signing the informed consent form (ICF).\n\n  * Subject must understand and voluntarily sign an ICF prior to any study-related assessments\u002Fprocedures.\n\n    ③ Subject is willing and able to adhere to the study visit schedule and protocol requirements.\n\n    ④ Subject has documented diagnosis of multiple myeloma, follicular lymphoma, or large B-cell lymphoma (including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, transformed follicular lymphoma, or transformed marginal zone lymphoma), and is receiving one of the following bispecific antibodies: Multiple Myeloma: Teclistamab, Elranatamab, Talquetamab, Cevostamab, ABBV383 Lymphomas: Mosunetuzumab, Glofitamab, Epcoritamab, Odronextamab\n\n    ⑤ Subject has documented clinically significant CMV infection, defined as: A. Onset of CMV end-organ disease (Appendix 1), or B. Initiation of anti-CMV pre-emptive therapy based on documented CMV viremia ≥500 IU\u002FmL in two consecutive assessments (≥1 day apart) and the clinical condition of the subject Note: Prior therapy with ganciclovir, valganciclovir, foscarnet, or cidofovir is allowed.\n    * ECOG performance status of 0, 1, or 2. ⑦ Individual of childbearing potential (IOCBP) must: A. Have two negative pregnancy tests before study treatment, and agree to ongoing testing.\n\nB. Commit to true abstinence or use two forms of contraception (one highly effective + one barrier method) starting 28 days prior to treatment, during treatment, and for 90 days after the last dose.\n\nNote: Definition of IOCBP includes menstruating individuals who are not postmenopausal for 12+ months or have not undergone permanent sterilization.\n\n⑧ Male subjects must: A. Practice true abstinence (monthly verified) or use a condom with partners who are pregnant or of childbearing potential during treatment, dose interruptions, and for 90 days after last dose, regardless of vasectomy status.\n\n⑨ Male subjects must not donate sperm during treatment and for 90 days after the last dose.\n\n⑩ Female subjects must not donate eggs during treatment and for 90 days after the last dose.\n\nExclusion Criteria:\n\n* Requires ganciclovir, valganciclovir, foscarnet, or cidofovir for non-CMV indications or requires co-administration with maribavir.\n\n  * Known hypersensitivity to maribavir. ③ CMV disease involving the CNS (retinitis alone is allowed). ④ Received allogeneic SCT within 1 year or autologous SCT within 12 weeks prior to study treatment.\n\nAllogeneic SCT recipients must not have active GVHD. ⑤ Any significant medical condition, infection, lab abnormality, or psychiatric illness posing unacceptable risk.\n\n* Any condition that may confound data interpretation. ⑦ Any of the following laboratory abnormalities:\n\nA. Creatinine clearance \\\u003C10 mL\u002Fmin or requiring dialysis (Cockcroft-Gault formula used):\n\n* Males: CrCl = (140 - age) × weight (kg) \u002F (72 × creatinine \\[mg\u002FdL\\])\n* Females: Multiply above result by 0.85 B. AST or ALT \\>5 × ULN C. Total bilirubin \\>3 × ULN (except Gilbert's syndrome)\n\n  * Gastrointestinal disease or surgery (e.g., gastric bypass) that affects maribavir absorption.\n\n    * Severe vomiting, diarrhea, or GI illness within 24 hours before first dose. ⑩ Use of immunosuppressive medication within 14 days before study treatment, except: A. Intranasal, inhaled, topical, or local corticosteroid injections B. Systemic corticosteroids ≤10 mg\u002Fday of prednisone or equivalent C. Premedication for hypersensitivity (e.g., CT scan premed) ⑪ Requires mechanical ventilation or vasopressors at enrollment. ⑫ Positive for HIV, active or chronic HBV, active HAV or HCV: A. Known HIV infection B. Positive HBsAg (acute or chronic); HBV DNA PCR required for anti-HBcAb(+) patients.\n* EXCEPTION: Isolated anti-HBs with known HBV vaccination\n* EXCEPTION: anti-HBc(+), HBsAg(-), anti-HBsAb(-) with negative HBV DNA C. HCV antibody and RNA positive ⑬ Pregnant, breastfeeding, or planning pregnancy during study participation.","19 Years",{"count":152,"type":21},[100],"This is an open-label, single arm, multicenter study to evaluate the feasibility of maribavir treatment in multiple myeloma and lymphoma patients undergoing bispecific antibody treatment and experiencing treatment emergent CMV events",[25],[201,202,203],"CMV","MM","Lymphoma","2025-11-26",{"date":206,"type":34},"2025-12-04",{"date":182,"type":34},{"date":209,"type":21},"2028-01-31",{"name":211,"class":41},"Seoul National University Hospital",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":195,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":42},"100558769","a-study-of-livtencity-maribavir-in-adults-with-cytomegalovirus-cmv-infection-after-transplantation-in-south-korea-100558769","NCT06555432","A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea","Post-Marketing Surveillance (Usage Results Study) of LIVTENCITY Tablet (Maribavir) for the Approved Indications in South Korea","Inclusion Criteria:\n\n* Participants with post-transplant CMV infection and\u002For disease who are refractory and\u002For resistant to one or more prior therapy including ganciclovir, valganciclovir, cidofovir or foscarnet.\n* Participants with age greater than or equal to (\\>=) 19 years.\n* Initiate first treatment course with maribavir.\n* Voluntarily consent to participate in the study.\n\nExclusion Criteria:\n\n* Participants for whom LIVTENCITY Tablet (maribavir) is contraindicated as per product label.\n* Participants previously treated with maribavir in any study or as marketed drug.\n* Participants actively participating in other clinical trials of post-transplant CMV infection treatment or with other experimental treatments.",{"count":220,"type":21},168,"Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. LIVTENCITY (Maribavir) is a medicine approved for treating CMV infection in adults after transplant in South Korea.\n\nThe main aim of this study is to learn how safe and effective LIVTENCITY (Maribavir) is in treating adults with CMV infection after transplant in a routine clinical practice setting.\n\nDuring the study, a participant's data will be collected for about 5 months (20 weeks). The study does not have fixed visits to the hospital, but it is recommended to visit the study doctor approximately 6 times during study.",[25],[224],"Drug Therapy","2025-11-14",{"date":227,"type":34},"2025-11-18",{"date":229,"type":34},"2024-11-14",{"date":231,"type":21},"2028-10-01",{"name":63,"class":64},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":242,"conditions":243,"keywords":244,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":42},"100560455","a-survey-of-maribavir-tablets-in-participants-with-cytomegalovirus-infection-100560455","NCT06577363","A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection","Special Drug Use Surveillance of LIVTENCITY Tablets 200mg (All-Case Investigation)","Inclusion Criteria:\n\n\\- All participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation).\n\nExclusion Criteria:\n\n\\- None",{"count":241,"type":21},250,"This study is a survey in Japan of Maribavir tablets used to treat participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation).\n\nThe main aim of the study is to check if treatment with Maribavir can protect Japanese people against CMV infection, and to check side effect from the study treatment. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.\n\nDuring the study, participants with CMV infection will take Maribavir tablets according to their clinic's standard practice. The study doctors will check for side effects from Maribavir tablets for 27 weeks.",[25],[224],"2025-10-02",{"date":247,"type":34},"2025-10-07",{"date":249,"type":34},"2024-08-28",{"date":251,"type":21},"2031-08-30",{"name":63,"class":64},{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":263,"conditions":264,"keywords":265,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":274},"100568182","a-study-of-maribavir-in-adults-with-post-transplant-cytomegalovirus-cmv-infection-in-belgium-100568182","NCT06677892","A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium","Prospective, Non-interventional Study to Describe The Use of Maribavir and Its Effectiveness in Patients With Post-transplant Cytomegalovirus Infection\u002FDisease in Line With Belgian Reimbursement Conditions (The MARIBEL Study)","MARIBEL","Inclusion Criteria:\n\n* Participant signed an informed consent form.\n* Aged greater than or equal to (\\>=) 18 years at the time of consent.\n* Received an HSCT\u002FSOT.\n* Diagnosed with CMV infection\u002Fdisease any time after the HSCT\u002FSOT date.\n* Starting maribavir for the first time and in line with the Belgian reimbursement criteria.\n\nExclusion Criteria:\n\n• Participant treated with maribavir before the start of the study.",{"count":262,"type":21},75,"Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant.\n\nThe main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with CMV infection after transplant in Belgium in line with the Belgian reimbursement criteria.\n\nDuring the study, a participant's data will be collected for 2 years. The study does not have fixed visits to the hospital, but it is recommended collect data from routine visits and contacts.",[25],[224],"2025-09-02",{"date":268,"type":34},"2025-09-09",{"date":270,"type":34},"2025-02-24",{"date":272,"type":21},"2026-09-01",{"name":63,"class":64},9]